MANNATECH INC MTEX
Nasdaq · XNAS · stock · Medicinal Chemicals & Botanical Products
Chart by TradingView
2/9
Piotroski F — financial health
-1.37
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $108.0M | -$15.2M | $81.0M | -$4.3M | -$5.2M |
| 2024 | $117.9M | $2.5M | $91.5M | $2.0M | $8.6M |
| 2023 | $132.0M | -$2.2M | $102.9M | -$3.1M | $10.5M |
| 2022 | $137.2M | -$4.5M | $104.1M | -$3.7M | $14.2M |
| 2021 | $159.8M | $9.8M | $125.6M | $10.1M | $24.4M |
| 2020 | $151.4M | $6.3M | $115.9M | $5.1M | $26.0M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -1.37 (distress)
- Working capital / assets 0.061
- Retained earnings / assets -0.468
- EBIT / assets -0.014
- Equity / liabilities -0.148
Source: SEC EDGAR filings · CIK 0001056358 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.